{"id":391115,"date":"2016-06-20T00:00:00","date_gmt":"2016-06-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrid0005-2016-biopharma-human-immunodeficiency-virus-current-treatment-us-2016\/"},"modified":"2026-03-31T09:02:04","modified_gmt":"2026-03-31T09:02:04","slug":"cutrid0005-2016-biopharma-human-immunodeficiency-virus-current-treatment-us-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrid0005-2016-biopharma-human-immunodeficiency-virus-current-treatment-us-2016\/","title":{"rendered":"Human Immunodeficiency Virus | Current Treatment | US | 2016"},"content":{"rendered":"<p>The Human Immunodeficiency Virus (HIV) market is seeing growth due to the uptake of new premium-priced antiretroviral agents, particularly the latest single-tablet regimens (STRs) with improved side-effect profiles that place an emphasis on safety and tolerability. Our Current Treatment content provides deep insights drawn from a survey of 103 infectious disease specialists and internal medicine physicians regarding the current and anticipated use of HIV regimens, including the recently approved STR Genvoya (elvitegravir\/emtricitabine\/tenofovir alafenamide\/cobicistat), by capturing patient and market share data, current prescribing trends, and anticipated changes in prescribing and treatment behavior in the United States today.<\/p>\n","protected":false},"template":"","class_list":["post-391115","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-human-immunodeficiency-virus","biopharma-therapy-areas-infectious-disease","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391115\/revisions"}],"predecessor-version":[{"id":394238,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391115\/revisions\/394238"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}